IMPROVE-CKD

improve-ckd-logo-2016

IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease

Principal Investigator: Dr Nigel Toussaint and Dr Eugenie Pedagogos
Project Officer: Andrea Valks (AKTN)
Trial Number: AKTN 10.01

Population: CKD stage 3b/4 patients
Intervention: Lanthanum carbonate (1500-3000mg) vs placebo, daily
Follow-up: 24 months
Primary outcome: Arterial compliance (PWV)
Status: Australian & New Zealand sites currently recruiting; and sites in Malaysia were seeking approval for participation

Recruitment end date: 31 December 2016
Follow-up end date: December 2018
Recruitment: 278/483 (44.67%)


Trial Summary:

Chronic kidney disease (CKD) is a significant health problem and is associated with an increased risk of cardiovascular (CV) disease. Vascular calcification and arterial stiffness (stiffening of the blood vessels and arteries) are very common in people with CKD, and are linked to increased death from CV events. This study aims to examine the ways in which treatment with a phosphate binder, Lanthanum Carbonate, may reduce vascular calcification and arterial stiffness to decrease CV events.